China Resources Double-Crane Pharmaceutical Co Ltd Strategic Asset Allocation Index
China Resources Double-Crane Pharmaceutical Co Ltd strategic asset allocation index. China Resources Double-Crane Pharmaceutical Co Ltd (600062) has a Strategic Asset Allocation Index of 31.8% as of June 2023. Strategic assets (PP&E of CN¥3.57 Billion plus long-term investments of CN¥-) total CN¥3.57 Billion, measured against net assets of CN¥11.24 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check 600062 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of China Resources Double-Crane Pharmaceutical Co Ltd (2000–2021)
Strategic asset allocation index of China Resources Double-Crane Pharmaceutical Co Ltd from 2000 to 2021. This chart shows how China Resources Double-Crane Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 22 annual periods from 2000 to 2021. As of June 2023, the index stands at 31.8%, representing strategic assets of CN¥3.57 Billion against net assets of CN¥11.24 Billion CNY.
China Resources Double-Crane Pharmaceutical Co Ltd Strategic Asset Allocation Index by Year (2000–2021)
China Resources Double-Crane Pharmaceutical Co Ltd strategic asset allocation index by year from 2000 to 2021. The table below presents the year-by-year Strategic Asset Allocation Index for China Resources Double-Crane Pharmaceutical Co Ltd from 2000 to 2021, covering 22 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see China Resources Double-Crane Pharmaceuti (600062) market capitalisation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 28.2% | CN¥2.96 Billion | CN¥2.96 Billion | CN¥- | CN¥10.48 Billion | ▼ -0.3 pp |
| 2020 | 28.5% | CN¥2.67 Billion | CN¥2.67 Billion | CN¥- | CN¥9.38 Billion | ▼ -2.1 pp |
| 2019 | 30.6% | CN¥2.66 Billion | CN¥2.62 Billion | CN¥34.27 Million | CN¥8.68 Billion | ▼ -3.0 pp |
| 2018 | 33.6% | CN¥2.66 Billion | CN¥2.63 Billion | CN¥22.81 Million | CN¥7.91 Billion | ▲ +2.3 pp |
| 2017 | 31.2% | CN¥2.45 Billion | CN¥2.45 Billion | CN¥2.11 Million | CN¥7.85 Billion | ▼ -2.5 pp |
| 2016 | 33.8% | CN¥2.38 Billion | CN¥2.36 Billion | CN¥16.48 Million | CN¥7.04 Billion | ▼ -4.5 pp |
| 2015 | 38.3% | CN¥2.47 Billion | CN¥2.44 Billion | CN¥21.69 Million | CN¥6.43 Billion | ▲ +2.2 pp |
| 2014 | 36.1% | CN¥2.05 Billion | CN¥2.05 Billion | CN¥- | CN¥5.68 Billion | ▼ -5.3 pp |
| 2013 | 41.5% | CN¥2.21 Billion | CN¥2.21 Billion | CN¥- | CN¥5.34 Billion | ▼ -5.4 pp |
| 2012 | 46.9% | CN¥2.21 Billion | CN¥2.21 Billion | CN¥- | CN¥4.71 Billion | ▲ +1.0 pp |
| 2011 | 45.9% | CN¥2.00 Billion | CN¥2.00 Billion | CN¥- | CN¥4.34 Billion | ▲ +2.9 pp |
| 2010 | 43.0% | CN¥1.69 Billion | CN¥1.69 Billion | CN¥- | CN¥3.93 Billion | ▼ -1.2 pp |
| 2009 | 44.2% | CN¥1.56 Billion | CN¥1.56 Billion | CN¥- | CN¥3.53 Billion | ▲ +2.1 pp |
| 2008 | 42.1% | CN¥1.33 Billion | CN¥1.33 Billion | CN¥- | CN¥3.15 Billion | ▼ -4.8 pp |
| 2007 | 46.8% | CN¥1.11 Billion | CN¥1.11 Billion | CN¥- | CN¥2.36 Billion | ▼ -18.3 pp |
| 2006 | 65.1% | CN¥1.30 Billion | CN¥1.30 Billion | CN¥- | CN¥2.00 Billion | ▼ -14.5 pp |
| 2005 | 79.6% | CN¥1.54 Billion | CN¥1.54 Billion | CN¥- | CN¥1.94 Billion | ▼ -10.3 pp |
| 2004 | 89.9% | CN¥1.55 Billion | CN¥1.55 Billion | CN¥- | CN¥1.73 Billion | ▲ +0.2 pp |
| 2003 | 89.6% | CN¥1.54 Billion | CN¥1.54 Billion | CN¥- | CN¥1.72 Billion | ▲ +19.8 pp |
| 2002 | 69.8% | CN¥1.12 Billion | CN¥1.12 Billion | CN¥- | CN¥1.60 Billion | ▲ +8.5 pp |
| 2001 | 61.3% | CN¥912.88 Million | CN¥912.88 Million | CN¥- | CN¥1.49 Billion | ▲ +8.4 pp |
| 2000 | 52.9% | CN¥452.36 Million | CN¥452.36 Million | CN¥- | CN¥855.27 Million | — |